US2020289038A1PendingUtilityA1

Analyte sensing biointerface

Assignee: DEXCOM INCPriority: Apr 15, 2005Filed: Jun 1, 2020Published: Sep 17, 2020
Est. expiryApr 15, 2025(expired)· nominal 20-yr term from priority
A61B 5/0031A61B 5/14532C12Q 1/001B33Y 80/00A61B 5/14865A61B 5/1486C12Q 1/006
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein is an analyte sensing biointerface that comprises a sensing electrode incorporated within a non-conductive matrix comprising a plurality of passageways extending through the matrix to the sensing electrode. Also disclosed herein are methods of manufacturing a sensing biointerface and methods of detecting an analyte within tissue of a host using an analyte sensing biointerface.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An implantable continuous glucose sensor system, comprising:
 a working electrode configured to measure a signal indicative of a glucose concentration;   a membrane disposed on the working electrode, wherein the membrane comprises a biointerface, wherein the biointerface comprises an electrically conductive material, wherein the biointerface is configured to promote a foreign body response that will not substantially attack or attempt to block sensing of glucose; and   electronics electrically coupled to the working electrode.   
     
     
         2 . The sensor of  claim 1 , wherein the biointerface comprises an enzyme. 
     
     
         3 . The sensor of  claim 2 , wherein the biointerface further comprises a resistance domain disposed over the enzyme. 
     
     
         4 . The sensor of  claim 1 , wherein the biointerface further comprises a bioactive agent. 
     
     
         5 . The sensor of  claim 1 , wherein the biointerface is substantially planar.

Join the waitlist — get patent alerts

Track US2020289038A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.